Clinical trials
catalyst calendar across sponsors →Studies where OLMA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 1 with posted results
Held by 10 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, Point72 Asset Management, L.P., Duquesne Family Office LLC, Qube Research & Technologies Ltd, CITADEL ADVISORS LLC, +5 more) · FINRA short interest 18.2 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerNCT07085767Progression-Free Survival (PFS)Randomized · Triple-masked · Treatment | Phase 3 | Recruiting | Drug: Palazestrant, Letrozole-matching placebo, Ribociclib, Letrozole, Palazestrant matching-placebo | Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma | 1,000 | Dec 2028 | ≤ 865 d | 2026-08-17 |
| Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerNCT05508906Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Palazestrant, Ribociclib, Alpelisib, Everolimus, Atirmociclib | Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer, Locally Advanced Breast Cancer | 190 | 2027-12-31 | in 499 d | 2025-10-22 |
| Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsNCT06784193Number of participants with dose-limiting toxicities in the Dose Escalation ArmsRandomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: OP-3136, Fulvestrant, Palazestrant | Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer, Fulvestrant, Palazestrant | 180 | 2027-05-30 | in 284 d | 2025-10-10 |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738Dose-Selection Part: Incidence of adverse eventsRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Palazestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane | Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma | 510 | 2026-10-31 | in 73 d | 2026-08-13 |
| A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer PatientsNCT05266105Incidence of Dose Limiting ToxicitiesNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Palazestrant, Palbociclib | Breast Cancer | 60 | Mar 2026 | — | 2025-11-24 |
| A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast CancerNCT04505826results2026-05-11Dose Limiting Toxicities (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: OP-1250 | Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer | 153 | 2024-07-30actual | — | 2026-05-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19